# Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

> **NCT06348147** · PHASE2 · SUSPENDED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 39 (estimated)

## Conditions studied

- Newly Diagnosed Multiple Myeloma
- Multiple Myeloma
- Autologous Stem Cell Transplantation

## Interventions

- **BIOLOGICAL:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06348147
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-07
- **Primary completion:** 2027-05
- **Final completion:** 2029-05
- **Target enrollment:** 39 (ESTIMATED)
- **Why stopped:** budget
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06348147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06348147, "Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06348147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*